Is your organization’s funding and time better used in pursuit of scientific breakthroughs, or infrastructure? Mispro offers state-of-the-art vivarium research facilities for preclinical in vivo drug development, available to biopharmaceutical companies of all sizes.

Companies are now empowered to keep early-stage preclinical in vivo studies in-house. Operating within the contract vivarium (CV) model offers the control and flexibility biotech startups need to increase productivity while removing infrastructure headaches, allowing them to focus on data validation, good science, and basic efficacy, particularly in point-of-contact (POC) studies.

‍

Flex your science, not your budget

‍

The contract vivarium model is the most strategically sound and risk-averse option for early-stage biotech startups conducting preclinical rodent studies, by removing the costs and operational complexities of staffing, compliance, and insurance - so your organization can focus solely on science.

Mispro’s fully-equipped turnkey animal research facilities are AAALAC-accredited, and accessible to multiple companies for in vivo preclinical R&D, typically with rodents. By providing a fully equipped, managed, and staffed space for research, the CV model offers biotechs a high quality, high-potential strategy for early-stage drug development.

“Running an in vivo research program is complex, time-consuming and expensive,” said Dr. Keith Astrofsky, DVM, Director of Operations at Mispro. “With our insource offering, Mispro provides the people, infrastructure, and know-how to run vivarium research facilities in a safe, humane, and compliant manner, giving back considerable time and resources to client companies so they can focus instead on their drug development programs.”